Drug Research
WHO Demands More Study On People Living With Long COVID
The WHO has urged nations to invest promptly in research, recovery, and rehabilitation in order to treat the post-COVID-19 syndrome seriously.
At least 17 million people in the 53 Member States of the WHO European Region may have encountered post-COVID-19...
Drug Research
$300mn Pledged By Novartis For European Biotherapeutics
The next-generation biotherapeutics will receive $300 million from Novartis, according to the company. To build a fully integrated, dedicated scientific environment to boost its capabilities and capacity for early technological development of biologics, the multi-year investment will be deployed...
Drug Research
Prior To FDA Prurigo Nodularis Ruling, Dupixent Wins Again
Dupixent, the immunology favourite developed by Sanofi and Regeneron Pharmaceuticals, is still on the rise. It has received back-to-back approvals this year for the treatment of eosinophilic esophagitis and paediatric eczema, and now the IL-4/IL-13 inhibitor has achieved a...
Drug Research
Long-Awaited Daxxify By Revance Will Compete With Botox
Revance Therapeutics may soon run into an identity problem with a product that is so eagerly awaited that some people mistakenly call it by the name of the firm. Daxxify, Revance's long-awaited Botox rival, has officially received FDA approval,...
Drug Research
Introduction of Anti-Evolocumab Antibodies From Bio-Rad
A group of type 1 antibodies recently made available by Bio-Rad Laboratories are intended to prevent the drug evolcumab from attaching to its target, human proprotein convertase subtilisin/kexin type 9. (PCSK9). These recombinant, sequence-defined antibodies are meant to create...
Drug Research
Merck Assesses 5 Years of Keytruda Lung Cancer Research
By demonstrating a massive survival benefit, Keytruda's Keynote-189 study precipitated a turning point in the development of lung cancer medications. Merck & Co. is now providing a five-year review of the data that rendered the PD-1 inhibitor the norm...
Drug Research
Modus Therapeutics Enrols First Patient To Explore Sevuparin
The treatment for paediatric patients with severe malaria is being evaluated through research.
The first patient has been enrolled in the SEVUSMART study, according to a statement from Modus Therapeutics, a firm that creates therapies for individuals who have significant unmet...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
